文献速递细胞病理与分子病理

分子检测对甲状腺结节细胞学诊断影响的本机构经验分析

Analyzing the impact of molecular testing on the cytological diagnosis of thyroid nodules: Insights from our institution's experience.
PubMed 文献 · Cancer Cytopathol · 2025-01-01

该研究回顾性分析2015至2023年共3992例甲状腺细针穿刺标本,按Bethesda系统分类,比较常规反射性分子检测实施前后的诊断变化。结果显示,实施分子检测后意义不明的异型性(AUS)比例从19.8%升至30.1%,AUS与恶性比值从5.4升至8.9,差异有统计学意义(p=.029)。

要点

  • 分子检测实施后AUS诊断率显著升高(19.8%→30.1%,p=.029)。
  • 不确定类别(III-V类)占全部穿刺的32%。
  • AUS与恶性比值由5.4升至8.9,提示诊断阈值变化。

核心结论

  • 实施分子检测与不确定细胞学诊断(尤其AUS)的显著增加相关。

研究设计与样本

  • 回顾性分析2015年1月至2023年12月共9年于UNC Health System进行的3992例甲状腺细针穿刺细胞学病例,按Bethesda系统分类并比较分子检测实施前后的数据。

主要发现

  • 3992例穿刺中,AUS占26.1%(1041例),FN占3.4%(136例),SFM占2.2%(89例),不确定类别合计32%(1266例)。
  • 分子检测实施前AUS率为19.8%,AUS与恶性比值为5.4;实施后AUS率升至30.1%,比值升至8.9。
  • AUS率的增加具有统计学意义(p=.029)。

关键数值与推荐

  • Bethesda系统分类:I类12.3%(490例),II类52.5%(2096例),III类26.1%(1041例),IV类3.4%(136例),V类2.2%(89例),VI类3.5%(140例)。

临床怎么用

  • 分子检测可能影响甲状腺结节细胞学诊断分类,尤其增加AUS诊断,临床解读时应结合分子结果与细胞学分类综合评估风险。

局限性

  • 本研究为单机构回顾性分析,摘要未报告分子检测的具体项目、阳性率及手术病理随访完整率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fine-needle aspiration cytology (FNAC) is a preferred method for evaluation of thyroid nodules. Under The Bethesda System for Reporting Thyroid Cytopathology, approximately 15%-30% of FNAC results fall into an indeterminate category: atypia of undetermined significance (AUS), follicular neoplasm (FN), and suspicious for malignancy (SFM), Bethesda classes III, IV, and V respectively. Molecular testing of indeterminate nodules helps evaluate the risk of malignancy and guide management decisions. This retrospective study assesses the impact of molecular testing on thyroid nodule classification in our institution, with an emphasis on indeterminate results. METHODS: A 9-year retrospective analysis (January 2015-December 2023) was conducted at the University of North Carolina Health System. FNAC cases were classified per The Bethesda System. Molecular testing results and, when available, surgical pathology outcomes were reviewed. The study compared pre- and post-implementation data of routine reflex molecular testing of thyroid nodule diagnosis. RESULTS: A total of 3992 thyroid aspirates were evaluated: 490 (12.3%) nondiagnostic (class I), 2096 (52.5%) benign (class II), 1041 (26.1%) AUS (class III), 136 (3.4%) FN (class IV), 89 (2.2%) SFM (class V), and 140 (3.5%) malignant (class VI). Indeterminate cytology (classes III-V) accounted for 32% of all aspirates (n = 1266). Before molecular testing, the AUS rate was 19.8% with an AUS:malignant ratio of 5.4. Post-implementation, the AUS rate rose to 30.1%, with a ratio of 8.9. This increase was statistically significant (p = .029). CONCLUSION: Implementation of molecular testing was associated with a significant rise in indeterminate cytologic diagnoses, particularly AUS.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Emechebe DY, Patil SA, Collins T, et al. Analyzing the impact of molecular testing on the cytological diagnosis of thyroid nodules: Insights from our institution's experience. Cancer Cytopathol. 2025. PMID: 41139993. doi:10.1002/cncy.70051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。